Skip to Main Content

An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection

Conditions

Hepatitis

What is the purpose of this trial?

Brief Summary:

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of therapeutic outcomes for patients with chronic hepatitis B (HBV) who are currently taking tenofovir alafenamide (TAF) relative to those patients following other treatment regimens. The study will address important clinical questions regarding the management of HBV with TAF and other oral therapies by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to TAF.

  • Trial with
    Target PharmaSolutions, Inc.
  • Start Date
    01/30/2019
  • End Date
    01/30/2020
Trial Image

For more information about this study, contact:

Hong Chau

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    02/06/2019
  • Study HIC
    #2000024189